IONS Ionis Pharmaceuticals Inc.

72.99
+0.32  (+0%)
Previous Close 72.67
Open 72.53
Price To Book 9.64
Market Cap 10101652064
Shares 138,397,754
Volume 2,181,791
Short Ratio
Av. Daily Volume 1,187,332

NewsSee all news

  1. Hedge Funds Dropped The Ball On Ionis Pharmaceuticals, Inc. (IONS)?
  2. 4 Large-Cap Stocks Worth Looking Into Right Now
  3. Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted
  4. Here's Why Ionis Pharmaceuticals Slumped Today
  5. NASDAQ Back Above 8,000

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial initiation announced October 13, 2017.
IONIS-MAPTRx
Alzheimer's disease
Phase 2b data due 1H 2020.
AKCEA-ANGPTL3-LRx
Rare hyperlipidemias
Phase 2b data due 1H 2020.
AKCEA-APOCIII-LRx
Hyperlipoproteinemia and established cardiovascular disease
First patient enrolled in Phase 3 trial announced January 28, 2019.
IONIS-HTT Rx
Huntington's Disease
Phase 2 data presented at AHA November 2018 - endpoints met.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
FDA Approval announced October 5, 2018,
Inotersen (IONIS-TTRRx)
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2b data due mid-2019.
IONIS-FXIRx
End-stage renal disease
CRL issued August 27, 2018.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
Inotersen (IONIS-TTRRx)
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.
Phase 1/2 data to be presented at AAN in late-breaker May 7, 2019. Abstracts embargoed until May 3, 2019.
IONIS-SOD1Rx / BIIB067
Amyotrophic lateral sclerosis (ALS)
Phase 2 trial to be initiated early 2019.
IONIS-FB-LRx
Geographic Atrophy (GA)
Phase 1b/2 data presented at ESMO 2018. 23% PR/CR.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 1/2 data and Phase 3 trial initiation due 2019.
AKCEA-TTR-LRx
hATTR Amyloidosis

Latest News

  1. Hedge Funds Dropped The Ball On Ionis Pharmaceuticals, Inc. (IONS)?
  2. 4 Large-Cap Stocks Worth Looking Into Right Now
  3. Why A Highly Rated Biotech With A 54% Gain This Year Is Being Gutted
  4. Here's Why Ionis Pharmaceuticals Slumped Today
  5. NASDAQ Back Above 8,000
  6. 5 Stocks to Sell as They Climb to New Highs
  7. S&P Streak Ends as Stocks Step Back
  8. See what the IHS Markit Score report has to say about Ionis Pharmaceuticals Inc.
  9. Ionis Pharmaceuticals to Provide Corporate Update at 2019 Annual Meeting of Stockholders
  10. 3 Stocks That Have Doubled and Still Have Room to Grow
  11. 7 A-Rated Healthcare Stocks for Industry Expansion
  12. 1 Biotech That Biogen Should Buy ... but Probably Won't
  13. Achillion Meets Enrollment Target in Kidney Disease Studies
  14. Achillion Completes Enrollment in Rare Blood Disorder Study
  15. S&P Fights Past Growth Concerns to Reclaim 2800
  16. Ionis announces appointment of Brett P. Monia Ph.D. to its board of directors
  17. Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19)
  18. IBD Stock Of The Day Obliterates Earnings Views And Eyes New Buy Point
  19. 6 of the Most Expensive Stocks That Could Go On Sale